Drug regulator oversight sought for nutraceuticals; NGO flags quality, pricing concerns

# NGO Seeks Drug Rules For Nutraceuticals

**By Staff Reporter, Health Policy Desk | April 19, 2026**

On Sunday, April 19, 2026, a prominent health advocacy non-governmental organization (NGO) formally petitioned the Union Health Ministry in New Delhi to shift the regulatory oversight of nutraceuticals from food safety authorities to India’s apex drug regulator. The urgent appeal stems from alarming investigations highlighting widespread substandard quality, unverified therapeutic claims, and exorbitant pricing within the rapidly expanding dietary supplement market. By demanding that these products be reclassified under the Central Drugs Standard Control Organisation (CDSCO), advocates aim to enforce pharmaceutical-grade scrutiny. This move seeks to ensure consumer safety and fair pricing in a billion-dollar sector that has long operated in a complex regulatory grey zone. [Source: Hindustan Times | Additional: Public Health Policy Records].

## Identifying the Quality Crisis in Supplements

The demand for regulatory overhaul is largely driven by a comprehensive dossier presented by the NGO, which meticulously documents the declining quality standards in the Indian nutraceutical market. Nutraceuticals—a broad category encompassing dietary supplements, multivitamins, minerals, probiotics, and herbal extracts—are currently regulated as “foods for special dietary uses” under the Food Safety and Standards Authority of India (FSSAI).

However, recent independent audits have flagged a concerning disparity between what is printed on the label and what is contained in the actual product. The NGO’s report highlights that nearly 40% of the randomly sampled nutraceuticals purchased from both retail pharmacies and e-commerce platforms failed to meet their declared nutritional values. In some egregious cases, the active ingredients were either entirely absent or present in sub-therapeutic quantities, rendering the products functionally useless.

Furthermore, the lack of stringent pre-market clinical trials for nutraceuticals allows manufacturers to make borderline therapeutic claims. While explicit medical claims (such as “cures diabetes” or “prevents heart disease”) are prohibited under FSSAI rules, manufacturers frequently utilize clever phrasing (such as “supports healthy blood sugar levels” or “promotes cardiovascular health”) to circumvent these restrictions. This marketing strategy often misleads vulnerable patients into substituting prescribed, clinically proven medications with unverified dietary supplements, posing severe public health risks.

## The Pricing Discrepancy: A Loophole Exploited

Beyond quality control, the NGO’s petition heavily criticizes the unchecked pricing structure of the nutraceutical industry. Because these products are legally classified as food rather than drugs, they fall completely outside the purview of the National Pharmaceutical Pricing Authority (NPPA). The NPPA is responsible for capping the prices of essential medicines in India, ensuring that life-saving drugs remain affordable for the general populace.

Nutraceuticals enjoy no such price caps. The NGO’s analysis reveals astonishing retail markups, sometimes exceeding 1,000% of the manufacturing cost. **Key findings regarding pricing anomalies include:**

* **Identical Formulations, Different Prices:** A standard Vitamin D3 formulation (60,000 IU) registered as a prescription drug under the CDSCO costs significantly less due to NPPA regulations. The identical chemical formulation, when marketed as a “health supplement” under an FSSAI license, can be priced up to five times higher.
* **Marketing-Driven Costs:** Without the requirement to invest in rigorous clinical trials or pharmacological research, nutraceutical companies disproportionately allocate their budgets to aggressive marketing, celebrity endorsements, and high trade margins for pharmacists, which are ultimately passed on to the consumer.
* **Illusion of Premium Quality:** Higher price tags are frequently utilized as a psychological marketing tool to convince consumers of a product’s superior efficacy, despite a lack of empirical evidence supporting such claims.

By bringing nutraceuticals under the CDSCO, advocates argue that the government could subject these products to the Drugs (Prices Control) Order, standardizing costs and preventing corporate profiteering at the expense of consumer health. [Source: Hindustan Times | Additional: Market Pricing Analysis Reports].

## The FSSAI vs. CDSCO Regulatory Debate

The crux of the current controversy lies in the fundamental definitions of “food” versus “drug.” Under the Food Safety and Standards Act of 2006, Section 22 clearly delineates the rules for nutraceuticals, stipulating that they must not contain Schedule H drugs and must be safe for human consumption. The FSSAI’s primary mandate is food safety—ensuring products are free from adulterants, heavy metals, and biological contaminants.

Conversely, the CDSCO operates under the Drugs and Cosmetics Act of 1940. Its mandate is far more rigorous, focusing on a product’s safety, efficacy, and therapeutic impact. A drug must undergo pharmacokinetic profiling, stability testing, and phased clinical trials before it is approved for public use.

### Comparative Oversight Table

| Parameter | Current FSSAI Regulation (Food) | Proposed CDSCO Regulation (Drug) |
| :— | :— | :— |
| **Pre-Market Approval** | Minimal; focuses on safe ingredients. | Rigorous; requires clinical efficacy data. |
| **Manufacturing Standards** | General food hygiene (HACCP/GMP). | Strict pharmaceutical-grade GMP. |
| **Price Control** | None. Subject to free market dynamics. | Subject to NPPA price capping mechanisms. |
| **Labeling Claims** | General health and wellness support. | Specific, scientifically proven medical indications. |
| **Post-Market Surveillance** | Random food safety sampling. | Pharmacovigilance and adverse event reporting. |

Public health experts argue that because modern nutraceuticals are manufactured in the form of tablets, capsules, and syrups—and are consumed primarily for health optimization rather than basic caloric intake—they intrinsically function as pharmaceuticals and should be regulated as such.

## Explosive Market Growth and Consumer Vulnerability

The urgency of this regulatory pivot is underscored by the explosive growth of the Indian nutraceutical market. Triggered by a massive paradigm shift toward preventative healthcare following the global COVID-19 pandemic, Indian consumers have integrated daily supplements into their wellness routines at an unprecedented rate.

Industry projections for 2026 indicate that the Indian nutraceutical sector has crossed the $12 billion mark and is expanding at a Compound Annual Growth Rate (CAGR) of over 15%. This rapid expansion has attracted thousands of new domestic manufacturers and white-label brands, saturating the market.

While this growth has generated significant economic value, it has overwhelmed the FSSAI’s enforcement infrastructure. State-level food safety officers are primarily tasked with monitoring perishable foods, dairy, and agricultural produce. They often lack the specialized pharmacological training and laboratory bandwidth required to effectively assay complex multi-vitamin and herbal formulations. Consequently, substandard supplement brands operate with near impunity, relying on the low probability of regulatory audits.

## Expert Perspectives: Balancing Safety and Industry Viability

The proposal to transition nutraceuticals to CDSCO oversight has generated a polarized response from medical professionals and industry stakeholders.

Dr. Alok Vashistha, a clinical pharmacologist based in New Delhi, strongly supports the NGO’s petition. “We are witnessing an epidemic of supplement-induced hepatotoxicity (liver damage), particularly from unregulated herbal blends and high-dose fat-soluble vitamins,” he notes. “When a patient ingests a highly concentrated extract in a capsule form, it metabolizes exactly like an allopathic drug. It is scientifically contradictory to regulate it with the same leniency as a packet of biscuits. The CDSCO’s intervention is not just necessary; it is long overdue.”

On the other hand, industry representatives caution against knee-jerk regulatory overhauls. The Nutraceutical Manufacturers Association has expressed concerns that applying pharmaceutical regulations to health supplements could severely stifle market innovation and decimate small and medium enterprises (SMEs).

“Treating a basic Vitamin C or Ashwagandha supplement like a Schedule H prescription drug will exponentially increase compliance costs,” stated an industry spokesperson who wished to remain anonymous. “These costs will inevitably be passed on to the consumer, making preventative healthcare less accessible. Furthermore, international standards globally recognize supplements as a distinct category separate from allopathic drugs.” [Source: Independent Industry Policy Review 2026].

## Global Regulatory Frameworks Provide Context

When evaluating the NGO’s demands, it is helpful to look at how international bodies manage the food-drug intersection.

In the United States, the Food and Drug Administration (FDA) regulates dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Under DSHEA, supplements are treated as a special category of food, meaning they do not require FDA approval before hitting the market, though manufacturers are strictly prohibited from marketing them as treatments or cures for specific diseases.

Conversely, regulatory frameworks in Canada and Australia are far more stringent, aligning closer to what the Indian NGO is proposing. The Australian Therapeutic Goods Administration (TGA) classifies vitamins, minerals, and herbal supplements as “complementary medicines.” They are subjected to intense pre-market scrutiny regarding ingredient safety, manufacturing quality, and the substantiation of health claims.

The Indian proposal seeks to establish a framework more akin to the Australian model, transitioning away from the highly permissive US-style system currently mimicked by the FSSAI.

## Conclusion: Future Outlook and Policy Implications

The formal request by health advocates for drug regulator oversight marks a critical turning point for India’s burgeoning wellness sector. As consumer reliance on nutraceuticals deepens, the line between dietary supplementation and medical therapy continues to blur.

While an immediate and total handover of power from the FSSAI to the CDSCO may present logistical nightmares, policy experts suggest that the Union Health Ministry is likely to consider a hybrid approach. The formation of a specialized joint-regulatory task force—comprising experts from both the food safety authority and the drug control organization—could offer a pragmatic middle ground.

Such a committee would be uniquely positioned to draft a distinct “Nutraceutical Rulebook.” This could implement strict price caps and mandatory ingredient verification while avoiding the protracted clinical trial requirements of traditional pharmaceuticals.

Ultimately, the goal is clear: to ensure that when Indian consumers purchase a health supplement, they receive a product that is safe, scientifically validated, and fairly priced. As the government reviews the NGO’s compelling dossier, the nutraceutical industry braces for what could be the most significant regulatory reform in its history. Consumers and stakeholders alike will be watching closely as this public health debate unfolds in the coming months.